Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323671 | 0.90 | TNF (0.53) | TNFEGLN3ALDH1A1MAPTPOLB | |
| SCHEMBL15206424 | 0.86 | TNF (0.52) | TNFHDAC1EGLN3ALDH1A1MAPT | |
| SCHEMBL30459104 | 0.84 | PKM (0.57) | TNFALDH1A1MAPTPOLBHPGD | |
| SCHEMBL28307943 | 0.84 | PKM (0.57) | TNFALDH1A1MAPTPOLBHPGD | |
| SCHEMBL4064250 | 0.83 | EGLN3 (0.65) | TNFEGLN3ALDH1A1MAPTCREBBP | |
| SCHEMBL15323905 | 0.79 | BCHE (0.47) | TNFHDAC1EGLN3HPGDKMT2A | |
| SCHEMBL15205597 | 0.79 | TNF (0.45) | TNFHDAC1EGLN3ALDH1A1MAPT | |
| SCHEMBL15205271 | 0.79 | TNF (0.52) | TNFEGLN3ALDH1A1MAPTPOLB | |
| SCHEMBL8265791 | 0.78 | RAB9A (0.53) | ALDH1A1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL17537381 | 0.77 | TNF (0.66) | TNFALDH1A1MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| EP-2847165-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013150529-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013150529-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, INMT, IDO2 | TNF 2386/4885HDAC1 2198/4885EGLN3 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.